NCT03038490 is a NA clinical trial of ABOUND in Pressure Ulcers Stage III, sponsored by Our Lady of Maryknoll Hospital.

Who is sponsoring NCT03038490?

NCT03038490 is sponsored by Our Lady of Maryknoll Hospital.

What drugs are being tested in NCT03038490?

Interventions in NCT03038490: ABOUND.

What condition does NCT03038490 study?

NCT03038490 studies Pressure Ulcers Stage III, Pressure Ulcer, Stage IV.

Is NCT03038490 still recruiting?

NCT03038490 is currently status unknown. Last updated 31 January 2017.

Last reviewed 2017-01-31 · How we verify

NCT03038490

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Use of an Oral Mixture of Arginine, Glutamine and Beta-hydroxy-beta-methylbutyrate for Treatment of Pressure Ulcers

Status unknown NA Last updated 31 January 2017

What this trial tests

NA trial testing ABOUND in Pressure Ulcers Stage III in 90 participants. Status unknown.

Timeline

1 December 2016

Primary endpoint
30 September 2019

31 March 2020

Quick facts

Lead sponsor	Our Lady of Maryknoll Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 December 2016
Primary completion	30 September 2019
Estimated completion	31 March 2020
Sites	1 location across Hong Kong

Drugs / interventions tested

ABOUND

Conditions studied

Pressure Ulcers Stage III — all drugs for Pressure Ulcers Stage III →
Pressure Ulcer, Stage IV — all drugs for Pressure Ulcer, Stage IV →

Sponsor

Our Lady of Maryknoll Hospital

Who can join

18 and older, any sex, with Pressure Ulcers Stage III or Pressure Ulcer, Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate whether an oral nutritional supplement of a mixture of arginine, glutamine and HMB for a maximum period of four weeks is more beneficial than the standard dietary approach to the healing of pressure ulcers, and to examine whether the use of it can reduce admissions and length of hospitalizations for these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03038490 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Our Lady of Maryknoll Hospital
Last refreshed: 31 January 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03038490.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing